Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.1975.tb19246.xDOI Listing

Publication Analysis

Top Keywords

step colchicine
4
colchicine blocks
4
blocks secretion
4
secretion plasma
4
plasma protein
4
protein rat
4
rat liver
4
step
1
blocks
1
secretion
1

Similar Publications

This study described the biosynthesis of 4-hydroxydihydrocinnamaldehyde sharing with monolignol pathway and supplemented the biosynthesis of colchicine in G. superba, 4-hydroxydihydrocinnamaldehyde produced in tobacco BY2 cells provided an important stepstone. The precursor, 4-hydroxydihydrocinnamaldehyde (4-HDCA), participates in the biosynthesis of the carbon skeleton of colchicine, which is derived from L-phenylalanine.

View Article and Find Full Text PDF

Recurrent pericarditis (RP) has been traditionally regarded as a "nightmare" for both clinicians and patients. Until approximately a decade ago, available treatments were thin on the ground with non-steroidal anti-inflammatory medications, glucocorticoids, colchicine, and classical immunosuppressants being the only options. The first important step in the tale of RP was the advent of colchicine in clinical practice, which has been shown to halve the rate of first and subsequent pericarditis recurrences.

View Article and Find Full Text PDF

Transport of glycinin, the major soybean allergen, across intestinal epithelial IPEC-J2 cell monolayers.

J Anim Physiol Anim Nutr (Berl)

September 2024

College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, Shenyang, Liaoning, PR China.

Soybean allergen entering the body is the initial step to trigger intestinal allergic response. However, it remains unclear how glycinin, the major soybean allergen, is transported through the intestinal mucosal barrier. The objective of this study was to elucidate the pathway and mechanism of glycinin hydrolysates transport through the intestinal epithelial barrier using IPEC-J2 cell model.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness of a stepwise approach for treating cardiovascular risk factors based on European guidelines in patients with established atherosclerotic cardiovascular disease (ASCVD).
  • Researchers analyzed data from two large patient cohorts, identifying treatment goals focused on lowering LDL cholesterol and blood pressure, as well as promoting smoking cessation and various medication combinations.
  • Results indicated that using intensified Step 2 treatment options significantly reduces residual cardiovascular risk, improving patient outcomes and potentially decreasing events per 1000 patients treated in different European risk regions.
View Article and Find Full Text PDF

Inflammatory Biomarkers and Stroke Subtype: An Important New Frontier.

Neurology

January 2024

From the Department of Neurology (S.C.), University of Maryland, Baltimore; and Department of Neurology & Stroke Center (G.M.D.M.), Kantonsspital St. Gallen, Switzerland.

Inflammation is an established pathway in the formation, growth, and rupture of atherosclerotic plaques. Inflammation is thus essential to the pathogenesis of coronary heart disease and some types of ischemic stroke. The benefit of anti-inflammatory therapies, such as colchicine and the anti-IL1β canakinumab, is proven in patients with coronary heart disease, yet it remains unproven for patients with ischemic stroke.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!